---
title: "Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002424.SZ.md"
symbol: "002424.SZ"
name: "Guizhou Bailing Group Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-19T21:36:36.373Z"
locales:
  - [en](https://longbridge.com/en/quote/002424.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002424.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002424.SZ.md)
---

# Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)

## Company Overview

Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines and honey. Its products are used for cardiovascular, cough, cold, gynecological, and pediatric areas. The company was incorporated in 1999 and is headquartered in Anshun, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.gzbl.com](https://www.gzbl.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: D (0.66)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 187 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -9.87% |  |
| Net Profit YoY | -1745.95% |  |
| P/B Ratio | 2.13 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6785842138.78 |  |
| Revenue | 2929363713.62 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -3.14% | D |
| Profit Margin | -3.42% | D |
| Gross Margin | 45.89% | B |
| Revenue YoY | -9.87% | E |
| Net Profit YoY | -1745.95% | E |
| Total Assets YoY | -15.60% | E |
| Net Assets YoY | -0.66% | D |
| Cash Flow Margin | -593.89% | E |
| OCF YoY | -9.87% | E |
| Turnover | 0.45 | C |
| Gearing Ratio | 46.23% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Guizhou Bailing Group Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-9.87%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-1745.95%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.13",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6785842138.78",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2929363713.62",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-3.14%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-3.42%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "45.89%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-9.87%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-1745.95%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-15.60%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.66%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-593.89%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-9.87%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.45",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "46.23%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -68.52 | 207/215 | 3373.88 | 2744.42 | 1237.92 |
| PB | 2.16 | 95/215 | 2.51 | 2.25 | 1.87 |
| PS (TTM) | 2.35 | 49/215 | 2.58 | 2.32 | 1.93 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2023-08-24T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.92 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002424.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002424.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002424.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002424.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**